CCCC
C4 Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$321.73M
P/E Ratio
—
EPS
$-1.27
Beta
2.86
52W High
$3.82
52W Low
$1.21
50-Day MA
$2.79
200-Day MA
$2.45
Dividend Yield
—
Profit Margin
-292.10%
Forward P/E
—
PEG Ratio
—
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | $35.95M |
| Gross Profit (TTM) | $26.97M |
| EBITDA | $-102.53M |
| Operating Margin | -210.10% |
| Return on Equity | -44.40% |
| Return on Assets | -18.40% |
| Revenue/Share (TTM) | $0.43 |
| Book Value | $2.65 |
| Price-to-Book | 1.26 |
| Price-to-Sales (TTM) | 8.95 |
| EV/Revenue | 3.735 |
| EV/EBITDA | -0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 112.80% |
| Shares Outstanding | $110.18M |
| Float | $66.76M |
| % Insiders | 1.13% |
| % Institutions | 68.76% |
Historical Volatility
HV 10-Day
76.63%
HV 20-Day
80.98%
HV 30-Day
84.40%
HV 60-Day
99.79%
HV Rank
28.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($11.57 target)
1
Strong Buy7
BuyMore HEALTHCARE Stocks
Data last updated: 5/2/2026